Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report does not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers follows:

• Mark Hlatky, M.D.
  Professor of Health Research and Policy
  Professor of Medicine (Cardiovascular Medicine)
  Stanford University School of Medicine
  Stanford, CA
• David R. Holmes Jr., M.D.
  Professor of Medicine
  Division of Cardiovascular Diseases
  Mayo Clinic
  Rochester, MN
• Michael V. Holmes, M.R.C.P., M.Sc., M.B.B.S., B.Sc.
  UK MRC Population Health Scientist Fellow
  Institute of Cardiovascular Science
  Faculty of Population Health Sciences
  University College London (UCL)
  London, United Kingdom
• Rajnikanth Madabushi, Ph.D.
  Team Leader
  Division of Cardiovascular and Renal Products, Office of Clinical Pharmacology
  U.S. Food and Drug Administration
  Silver Spring, MD
• Alvin Mushlin, M.D. Sc.M.
  Professor and Chair, Department of Public Health
  Professor of Medicine
  Weill Cornell Medical College
  New York, NY
• Michael Pacanowski, Pharm.D., M.P.H.
  Associate Director for Genomics and Targeted Therapy
  Genomics Group, Office of Clinical Pharmacology
  U.S. Food and Drug Administration
  Silver Spring, MD
• Mary Southworth, Pharm.D.
  Deputy Director for Safety
  Division of Cardiovascular and Renal Products, Office of Clinical Pharmacology
  U.S. Food and Drug Administration
  Silver Spring, MD